Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

Michael Lübbert, Claudia Schmoor, Anne Hagemeijer, Björn Hackanson, Rainer Claus, Björn Rüter, Mathias Schmid, Ulrich Germing, MD, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, MD, Uwe Platzbecker, MD, Oliver Galm, Wolfram Brugger, Gerhard Heil, Pierre W. Wijermans, Konstanze Döhner, Hartmut Döhner

Blood (2011) 118 (21): 2609.

https://doi.org/10.1182/blood.V118.21.2609.2609

Published: 2011

Journal Articles

Decitabine (DAC) Treatment Induces Very Early In Vivo DNA Methylation and Transcriptome Changes in Primary AML Peripheral Blood Blasts

Rainer Claus, Dietmar Pfeifer, PhD, Maika Almstedt, Björn Hackanson, Manuela Zucknick, PhD, Christoph Plass, Michael Lübbert

Blood (2011) 118 (21): 1360.

https://doi.org/10.1182/blood.V118.21.1360.1360

Published: 2011

Journal Articles

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Michael Lübbert, Björn H. Rüter, Mathias Schmid, Rainer Claus, Ulrich Germing, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Pierre W Wijermans, Claudia Schmoor, Hartmut Döhner

Blood (2009) 114 (22): 4141.

https://doi.org/10.1182/blood.V114.22.4141.4141

Published: 2009

Journal Articles

Hemoglobin F Induction Is Frequent during Low-Dose 5-aza-2′-Deoxycytidine Treatment of Older AML/MDS Patients.

Rainer Claus, MD, Björn Hackanson, MD, Lena Kasten, Björn Rüter, MD, Emmanuel Bisse, MD PhD, Dieter Pfeifer, PhD, Michael Lübbert, MD PhD

Blood (2006) 108 (11): 4573.

https://doi.org/10.1182/blood.V108.11.4573.4573

Published: 2006

Journal Articles

Identification of ID4 as a Cooperating Second Hit for T Cell Lymphoma Development in PU.1 URE Δ/Δ Mice.

Bronwyn M. Owens, PhD, Li Yu, PhD, Ulrich Steidl, MD, Jeffrey L. Kutok, MD, Linda K. Clayton, PhD, Katharina Wagner, MD, Hiromi Iwasaki, MD, Chunhui Liu, Björn Hackanson, MD, Koichi Akashi, MD, Christoph Plass, PhD, Daniel G. Tenen, MD, Frank Rosenbauer, PhD

Blood (2005) 106 (11): 2613.

https://doi.org/10.1182/blood.V106.11.2613.2613

Published: 2005

NARROW

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

Decitabine (DAC) Treatment Induces Very Early In Vivo DNA Methylation and Transcriptome Changes in Primary AML Peripheral Blood Blasts

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Hemoglobin F Induction Is Frequent during Low-Dose 5-aza-2′-Deoxycytidine Treatment of Older AML/MDS Patients.

Identification of ID4 as a Cooperating Second Hit for T Cell Lymphoma Development in PU.1 URE Δ/Δ Mice.

Email alerts

ASH Publications

American Society of Hematology

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

Decitabine (DAC) Treatment Induces Very Early In Vivo DNA Methylation and Transcriptome Changes in Primary AML Peripheral Blood Blasts

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Hemoglobin F Induction Is Frequent during Low-Dose 5-aza-2′-Deoxycytidine Treatment of Older AML/MDS Patients.

Identification of ID4 as a Cooperating Second Hit for T Cell Lymphoma Development in PU.1 URE Δ/Δ Mice.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only